All AbMole products are for research use only, cannot be used for human consumption.
Pioglitazone (U 72107) is a selective peroxisome proliferator-activated receptor gamma stimulator. Pioglitazone (U 72107) selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. Pioglitazone (Actos) modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone (U 72107) reduces insulin resistance in the liver and peripheral tissues. Pioglitazone (U 72107) increases the expense of insulin-dependent glucose. Pioglitazone (U 72107) decreases withdrawal of glucose from the liver. Pioglitazone (U 72107) reduces quantity of glucose, insulin and glycated hemoglobin in the bloodstream.
J Cell Mol Med. 2020 Jun;24(12):6833-6845.
Seizure-induced impairment in neuronal ketogenesis: Role of zinc-α2-glycoprotein in mitochondria
Pioglitazone purchased from AbMole
 |
Source | J Cell Mol Med (2020 Jun). Figure 2. Pioglitazone (Abmole Bioscience, Houston, TX, USA) |
| Method | drug treatments | |
| Cell Lines | Neurons | |
| Concentrations | 10 μmol/L | |
| Incubation Time | 24 hours | |
| Results | Compared to the DMSO group, a 24-hour treatment with pioglitazone increased the levels of the ZAG protein (1.013 ± 0.135 vs 0.654 ± 0.090, P = 0.004, n = 4) and AZGP1 mRNA (1.474 ± 0.078 vs 1, P = 0.003, n = 3) (Figure 2B,C), while GW9662 significantly decreased the levels of the ZAG protein (0.361 ± 0.097 vs 0.654 ± 0.090, P = 0.013, n = 4) and AZGP1 mRNA (0.482 ± 0.153 vs 1, P = 0.002, n = 3) (Figure 2B,C). |
| Molecular Weight | 356.44 |
| Formula | C19H20N2O3S |
| CAS Number | 111025-46-8 |
| Solubility (25°C) | DMSO 30 mg/mL (Need ultrasonic and warming) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] David Karsek. Pioglitazone
[3] Huilin Tang, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis
| Related PPAR Products |
|---|
| SR1664
SR1664 is an antidiabetic compound that binds to PPARγ and can effectively inhibit CDK5-mediated phosphorylation of PPARγ with IC50 of 80 nM and Ki of 28.67 nM. |
| WY 14643 (Pirinixic Acid)
WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. |
| Rosiglitazone
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor. |
| GSK 3787
GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6). |
| Rosiglitazone maleate
Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
